Prognostic miR-1/-26a-1/-487b signature predicts glioma progression via SH3PXD2B/EFHD2 targeting
Abstract
Gliomas are aggressive brain tumors that remain challenging to diagnose and treat. Despite standard-of-care therapies, most patients recur, underscoring an unmet need for novel biomarkers to elucidate tumor evolution. MicroRNAs (miRNAs) play crucial roles in glioma biology by modulating tumorigenesis. We previously identified a non-invasive diagnostic/prognostic miRNA signature (miR-1-3p/miR-26a-1-3p/miR-487b-3p) which exerts oncosuppressive functions in glioma cells, prominently effecting the inhibition of invading targeting SH3PXD2A/SH3PXD2B/EFHD2 genes. Here, we investigated the miR-1/-26a-1/-487b- SH3PXD2A/SH3PXD2B/EFHD2 network as a progression indicator using datasets of primary/recurrent gliomas. We found that the three-miRNA signature is upregulated in primary vs. recurrent patients, whereas SH3PXD2A/SH3PXD2B/EFHD2 are downregulated in primary patients. It is worthy to note that, this network correlates with improved survival. These findings were validated by RT-qPCR in tissues of a paired-primary/recurrent cohort ( n = 42). Univariate and multivariate Cox-regression analyses showed that high miR-1-3p/miR-26a-1-3p/miR-487b-3p signature expression independently correlated with prolonged progression-free-survival in this cohort. Additionally, we developed a digital PCR multiplex clinical research assay (G-SMART), for the simultaneous absolute quantification of miR-1-3p/miR-26a-1-3p/miR-487b-3p, which may provide a fast and sensitive tool in the clinical setting. In conclusion, the miR-1-3p/miR-26a-1-3p/miR-487b-3p and its targets are key axes that are progressively dysregulated upon glioma progression. Hence, this regulatory network might offer a prognostic tool for disease monitoring, leading us to hypothesize a translational value of our findings for a more precise and patient-tailored approach.
Related
- An interpretable machine-learning signature predicts early triple-negative breast cancer recurrence but adds no prognostic value beyond clinicopathological factors in external validation
- Multi-omics profiling uncovers diagnostic biomarker panel, progression-associated subtypes, and prognostic signature in pediatric mitochondrial disease
- A CAVIN1/SULF1-associated myCAF signature predicts metastatic progression in colorectal cancer
- A kbhb-associated prognostic signature identifies TTLL12 as a promoter of lung adenocarcinoma progression associated with M2 macrophage infiltration.
- Metabolic signature of phosphoethanolamine and arginine pathways predicts prognosis and immunotherapy resistance in lung adenocarcinoma
BibTeX
@article{mendez2026prognostic,
title = {{Prognostic miR-1/-26a-1/-487b signature predicts glioma progression via SH3PXD2B/EFHD2 targeting}},
author = {Ana Belén Díaz Méndez and Marta Di Giuliani and Andrea Sacconi and Matteo Allegretti and Giulio Ranazzi and Sara Ramponi and Valeria Barresi and Anna Stroppa and Antonio Silvani and Andrea Costantini and Beatrice Astuccioni and Alessandro Di Maio and Mariantonia Carosi and Giulia Regazzo and Carlo Garufi and Maria Giulia Rizzo},
journal = {Scientific Reports},
year = {2026},
month = oct,
doi = {10.1038/s41598-026-76937-4},
url = {https://www.nature.com/articles/s41598-026-76937-4},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Prognostic miR-1/-26a-1/-487b signature predicts glioma progression via SH3PXD2B/EFHD2 targeting
AU - Ana Belén Díaz Méndez
AU - Marta Di Giuliani
AU - Andrea Sacconi
AU - Matteo Allegretti
AU - Giulio Ranazzi
AU - Sara Ramponi
AU - Valeria Barresi
AU - Anna Stroppa
AU - Antonio Silvani
AU - Andrea Costantini
AU - Beatrice Astuccioni
AU - Alessandro Di Maio
AU - Mariantonia Carosi
AU - Giulia Regazzo
AU - Carlo Garufi
AU - Maria Giulia Rizzo
PY - 2026
DA - 2026/10/27
JO - Scientific Reports
DO - 10.1038/s41598-026-76937-4
UR - https://www.nature.com/articles/s41598-026-76937-4
AB - Gliomas are aggressive brain tumors that remain challenging to diagnose and treat. Despite standard-of-care therapies, most patients recur, underscoring an unmet need for novel biomarkers to elucidate tumor evolution. MicroRNAs (miRNAs) play crucial roles in glioma biology by modulating tumorigenesis. We previously identified a non-invasive diagnostic/prognostic miRNA signature (miR-1-3p/miR-26a-1-3p/miR-487b-3p) which exerts oncosuppressive functions in glioma cells, prominently effecting the inhibition of invading targeting SH3PXD2A/SH3PXD2B/EFHD2 genes. Here, we investigated the miR-1/-26a-1/-487b- SH3PXD2A/SH3PXD2B/EFHD2 network as a progression indicator using datasets of primary/recurrent gliomas. We found that the three-miRNA signature is upregulated in primary vs. recurrent patients, whereas SH3PXD2A/SH3PXD2B/EFHD2 are downregulated in primary patients. It is worthy to note that, this network correlates with improved survival. These findings were validated by RT-qPCR in tissues of a paired-primary/recurrent cohort ( n = 42). Univariate and multivariate Cox-regression analyses showed that high miR-1-3p/miR-26a-1-3p/miR-487b-3p signature expression independently correlated with prolonged progression-free-survival in this cohort. Additionally, we developed a digital PCR multiplex clinical research assay (G-SMART), for the simultaneous absolute quantification of miR-1-3p/miR-26a-1-3p/miR-487b-3p, which may provide a fast and sensitive tool in the clinical setting. In conclusion, the miR-1-3p/miR-26a-1-3p/miR-487b-3p and its targets are key axes that are progressively dysregulated upon glioma progression. Hence, this regulatory network might offer a prognostic tool for disease monitoring, leading us to hypothesize a translational value of our findings for a more precise and patient-tailored approach.
SN - 2045-2322
ER -